THEMIS MEDICARE LTD
Add to watch list to get report alerts
BSE Code:
530199
NSE Code:
THEMISMED
Business Profile
Business Profile
Established in 1969, Themis Medicare (TML) is a joint venture pharmaceutical company with Gedeon Richter of Hungary. It was formerly known as Themis Chemicals and subsequently changed its name to Themis Medicare. It is engaged in the manufacturing and marketing of active pharmaceutical intermediates, bulk intermediates and formulations of synthetic and fermentation origin. TML has also developed several molecules including Arteether which is an artemisinin derivative and Feracrylum, a unique haemostatic hygroscopic agent. Various products marketed by the company include Thre, Atrostat, E-mal and T-ox capsules having an application in the treatment of tuberculosis, malaria, heart ailment and vitamin supplement respectively. Headquartered in Mumbai, the company has state-of-the-art manufacturing facilities at Vapi in Gujarat, Hyderabad and Haridwar in Uttaranchal. TML has a wholly owned overseas subsidiary, Themis Medicare Singapore.
Financials
Themis Medicare registered a 35.02% growth in net profits to Rs 40.13 million for the quarter ended in September 2007 from a profit of Rs 29.72 million for the quarter ended in September 2006.
Net Sales rose 30.57% to Rs 610.18 million for the quarter ended September 2007 from Rs 467.29 million for the quarter ended September 2006.
Total income rose 30.38% to Rs 613.61 million for the quarter ended September 2007, from Rs 470.61 million for the quarter ended September 2006.
The diluted earnings per share (EPS) of the company stood at Rs 4.87 in the quarter ended September 2007.
Recent Developments
26-JUL-07
Themis Laboratories signed a technology transfer agreement with Adventism Parma, a member of the sanofi-aventis Group, for fixed - dose combinations comprising glibenclamide (Daonil) and glimepiride (Amaryl), two best selling products from the sanofi-aventis research pipeline with sustained-release metformin through a unique technology developed by Themis Laboratories for the treatment of Type 2 diabetes.
09-JAN-07
Themis Medicare has entered into an agreement with M/S Darou Pakhsh Pharma Chem, (DPPC), Iran for erection and Technology supply in connection with establishing a manufacturing facility for Statins in Iran.